A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Eligibility

Age range: 18+ years
Sex: Male
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. * Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening * Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Exclusion Criteria: * Participant must not have history of brain metastases. * Participant must not have impaired cardiac…

Locations (15)

Stanford Cancer Center
Palo Alto, California
650-725-2078
Florida Cancer Specialists Sarasota Drug Development Unit
Sarasota, Florida
941-377-9993
Dana-Farber Cancer Institute
Boston, Massachusetts
000-000-0000
Memorial Sloan Kettering Cancer Center
New York, New York
646-422-4379
Duke Cancer Institute
Durham, North Carolina
919-668-8797
Local Institution - 0006
San Antonio, Texas

Summary

Eligibility

Interventions

Locations (15)